Ghrelin intronic lncRNAs, lnc-GHRL-3:2 and lnc-GHRL-3:3, as novel biomarkers in type 2 diabetes mellitus

References

• Barra, J., and Leucci, E., 2017. Probing Long Non-coding RNA-Protein Interactions. Frontiers in molecular biosciences, 4, 45.
   PubMed Web of Science ®Google Scholar
• Broglio, F., et al., 2001. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. The journal of clinical endocrinology & metabolism, 86 (10), 5083–5083.
   PubMed Web of Science ®Google Scholar
• Doogue, M.P., et al., 2009. Metformin increases plasma ghrelin in Type 2 diabetes. British journal of clinical pharmacology, 68 (6), 875–882.
   PubMed Web of Science ®Google Scholar
• Fang, Y., and Fullwood, M.J., 2016. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics proteomics bioinformatics, 14 (1), 42–54.
   PubMed Web of Science ®Google Scholar
• Fernandes, J.C.R., et al., 2019. Long non-coding RNAs in the regulation of gene expression: physiology and disease. Non-coding RNA, 5 (1), 17.
   PubMed Web of Science ®Google Scholar
• Gagnon, J., Sheppard, E., and Anini, Y., 2013. Metformin directly inhibits ghrelin secretion through AMP-activated protein kinase in rat primary gastric cells. Diabetes, obesity & metabolism, 15 (3), 276–279.
   PubMed Web of Science ®Google Scholar
• Ida, S., Murata, K., and Kaneko, R., 2017. Effects of metformin treatment on blood leptin and ghrelin levels in patients with type 2 diabetes mellitus. Journal of diabetes, 9 (5), 526–535.
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation, 2019. Worldwide toll of diabetes [online]. https://www.diabetesatlas.org/en/sections/worldwide-toll-of-diabetes.html [Accessed Access Date
   Google Scholar
• Kojima, M., et al., 1999. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 402 (6762), 656–660.
   PubMed Web of Science ®Google Scholar
• Leti, F., and Distefano, J.K., 2017. Long noncoding RNAs as diagnostic and therapeutic targets in type 2 diabetes and related complications. Genes, 8, 207.
   PubMed Web of Science ®Google Scholar
• Li, X., et al., 2017. The diagnostic value of whole blood lncRNA ENST00000550337.1 for Pre-diabetes and type 2 diabetes mellitus. Experimental and clinical endocrinology & diabetes: official journal, German society of endocrinology [and] German diabetes association, 125 (6), 377–383.
   PubMed Web of Science ®Google Scholar
• Ling, C., and Rönn, T., 2019. Epigenetics in human obesity and type 2 diabetes. Cell metabolism, 29 (5), 1028–1044.
   PubMed Web of Science ®Google Scholar
• Mattick, J.S., and Gagen, M.J., 2001. The evolution of controlled multitasked gene networks: the role of introns and other noncoding rnas in the development of complex organisms. Molecular biology and evolution, 18 (9), 1611–1630.
   PubMed Web of Science ®Google Scholar
• Pertea, M., 2012. The human transcriptome: an unfinished story. Genes, 3 (3), 344–360.
   PubMed Web of Science ®Google Scholar
• Reimer, M.K., Pacini, G., and AhréN, B., 2003. Dose-dependent inhibition by ghrelin of insulin secretion in the mouse. Endocrinology, 144 (3), 916–921.
   PubMed Web of Science ®Google Scholar
• Rezaie, P., Mazidi, M., and Nematy, M., 2015. Ghrelin, food intake, and botanical extracts: a review. Avicenna journal of phytomedicine, 5 (4), 271–281.
   PubMed Web of Science ®Google Scholar
• Rinn, J.L., and Chang, H.Y., 2012. Genome regulation by long noncoding RNAs. Annual review of biochemistry, 81, 145–166.
   PubMed Web of Science ®Google Scholar
• Ruan, Y., et al., 2018. Circulating LncRNAs analysis in patients with type 2 diabetes reveals novel genes influencing glucose metabolism and islet β-cell function. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 46 (1), 335–350.
   PubMedGoogle Scholar
• Sathishkumar, C., et al., 2018. Linking a role of lncRNAs (long non-coding RNAs) with insulin resistance, accelerated senescence, and inflammation in patients with type 2 diabetes. Human Genomics, 12 (1), 41–41.
   PubMedGoogle Scholar
• Sun, Y., et al., 2017. Identification of long non-coding RNAs biomarkers associated with progression of endometrial carcinoma and patient outcomes. Oncotarget, 8 (32), 52604–52613.
   PubMedGoogle Scholar
• Tong, J., et al., 2010. Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes, 59 (9), 2145–2151.
   PubMed Web of Science ®Google Scholar
• Topyildiz, F., et al., 2016. Exenatide treatment causes suppression of serum ghrelin levels following mixed meal test in obese diabetic women. Journal of diabetes research, 2016, 1–1309502.
   Web of Science ®Google Scholar
• Verhulst, P.-J., and Depoortere, I., 2012. Ghrelin's second life: from appetite stimulator to glucose regulator. World journal of gastroenterology, 18 (25), 3183–3195.
   PubMed Web of Science ®Google Scholar
• Wang, K.C., and Chang, H.Y., 2011. Molecular mechanisms of long noncoding RNAs. Molecular cell, 43 (6), 904–914.
   PubMed Web of Science ®Google Scholar
• Wang, X., et al., 2017. Aberrant expression of long non-coding RNAs in newly diagnosed type 2 diabetes indicates potential roles in chronic inflammation and insulin resistance. Cellular physiology and biochemistry, 43 (6), 2367–2378.
   PubMedGoogle Scholar
• Zhao, X.-Y., and Lin, J.D., 2015. Long noncoding RNAs: a new regulatory code in metabolic control. Trends in biochemical sciences, 40 (10), 586–596.
   PubMed Web of Science ®Google Scholar